Senior Director
Pfizer, Inc.
Kui Huang serves as the Epidemkology Strategic Lead for Rare Disease/Internal Medicine in Global Medical Epidemology at Pfizer. She has more than 15 years of experience leveraging epidemiology and real-world data (RWD) research strategies to support business and regulatory activities throughout the lifecycle of products in mutiple therapitic areas including Oncology, Vaccine, Rare Disease, and Internal Medicine. She has successfully designed and/or led implementation of more than 50 observational and RWD studies in US, Europe and Asia including the first post-approval commitment study using Chinese RWD, which paved the way for the future use of RWD/real world evidence to support regulatory decision making in China. She has authored or co-authored more than 40 articles in peer-reviewed journals. She is the lead author for the chapter “Benefit-Risk Assessment in Risk Management” in Pharmacoepidemiology 5th Edition in Chinese. Prior to entering the pharmaceutical industry, she worked as a biostatistician at academia and as an epidemiology fellow at CDC in the US. She holds a master in Epidemiology & Biostatistisics and Maternal & Child Health from Boston University and a PhD in Epidemiology with concentration on genetic epidemiology from UNC-Chapel Hill.
